The Topical Nanodelivery of Vismodegib Enhances Its Skin Penetration and Performance <i>In Vitro</i> While Reducing Its Toxicity <i>In Vivo</i>

• Main Authors: Maria Natalia Calienni (Author), Daniela Maza Vega (Author), C. Facundo Temprana (Author), María Cecilia Izquierdo (Author), David E. Ybarra (Author), Ezequiel Bernabeu (Author), Marcela Moretton (Author), Fernando C. Alvira (Author), Diego Chiappetta (Author), Silvia del Valle Alonso (Author), María Jimena Prieto (Author), Jorge Montanari (Author)
• Format: Book
• Published: MDPI AG, 2021-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

Vismodegib is a first-in-class inhibitor for advanced basal cell carcinoma treatment. Its daily oral doses present a high distribution volume and several side effects. We evaluated its skin penetration loaded in diverse nanosystems as potential strategies to reduce side effects and drug quantities. Ultradeformable liposomes, ethosomes, colloidal liquid crystals, and dendrimers were able to transport Vismodegib to deep skin layers, while polymeric micelles failed at this. As lipidic systems were the most effective, we assessed the <i>in vitro</i> and <i>in vivo</i> toxicity of Vismodegib-loaded ultradeformable liposomes, apoptosis, and cellular uptake. Vismodegib emerges as a versatile drug that can be loaded in several delivery systems for topical application. These findings may be also useful for the consideration of topical delivery of other drugs with a low water solubility.

Item Description

10.3390/pharmaceutics13020186
1999-4923